RC28-E
Phase 2Biologic
RC28-E is one of 61 biologic programs targeting Wet Age-Related Macular Degeneration. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
99 competitors in Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Atacand
AstraZenecaPhase 3
Bayer Aspirin
BayerPhase 3
Sandostatin
NovartisPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zocor
OOrganon and Co
Phase 3
Atacand
IIstituto Clinico Humanitas
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Octreotide Depot
NovartisPhase 3
Pred Forte
NovartisPhase 2
Alphagan
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Wet Age-Related Macular Degeneration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC28-E. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- RRemeGen Co., Ltd.